Biofrontera AG

Biofrontera AG Discusses Major Changes in Collaboration with Biofrontera Inc.

Biofrontera AG Reports 55% Q1 2025 Revenue Growth, EBIT Turns Positive

Biofrontera AG Annual General Meeting Approves Multiple Proposals

Biofrontera AG Announces Executive Compensation Policy

Biofrontera AG has announced the pre-announcement of its financial report for the year 2025, covering the period from January 1, 2025, to December 31, 2025. The report will be published on April 17, 2026. The company operates in the regulated markets of Dusseldorf and Frankfurt, as well as in the free markets of Munich, Stuttgart, and Tradegate.

pressetext

Pre-announcement of a financial report according to articles 114 - 117 WpHG

BFRIW

Biofrontera reports rise in Q4 revenue, turns profitable

businessinsider

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)

First Trust NYSE Arca Biotech Index Fd

Biofrontera reports rise in Q4 revenue, turns profitable

BFRI

Biofrontera AG has announced its financial guidance for FY 2026, projecting sales revenue between EUR 14 million and EUR 16 million, with adjusted EBITDA expected to range from EUR +3.5 million to EUR +5.1 million. The guidance excludes earn-out from Biofrontera Inc. related to U.S. sales of Ameluz, anticipated to be between EUR 3.5 million and EUR 4.5 million. The company notes that U.S. operations will be classified as discontinued under IFRS accounting standards, affecting reported sales revenue and EBITDA.

Biofrontera

Financial Guidance for FY 2026

Biofrontera AG has raised its forecast for fiscal year 2025, expecting EBITDA to be between EUR 3.5 million and EUR 5 million, up from the previous estimate of EUR 1.5 million to EUR 3.5 million. The revenue forecast remains unchanged at EUR 17 million to EUR 20 million. This announcement was made in accordance with article 17 MAR.

PTA-Adhoc: Biofrontera AG: Forecast Increase

Biofrontera AG reported a 14.8% increase in total revenues for the first nine months of 2025, reaching EUR 12,315 thousand. The company saw significant growth in Germany with a 21.6% increase in sales. EBITDA improved from a negative EUR 4,460 thousand in 2024 to a positive EUR 1,837 thousand in 2025. Despite a decline in EU distributor sales, growth in direct sales markets and the US offset this. The restructuring with Biofrontera Inc. and cost-saving measures strengthened profitability.

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025

Biofrontera AG has completed the sale of its U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc., transferring all related assets, liabilities, and rights. In return, Biofrontera AG receives a 10% equity stake in Biofrontera Inc. and an earn-out based on U.S. Ameluz® sales until 2043. The agreement also transfers ongoing litigation responsibilities to Biofrontera Inc., allowing Biofrontera AG to focus on its European operations. The operational transfer is expected to be finalized by Q1 2026, streamlining Biofrontera AG's structure and reducing costs.

Biofrontera AG completes sale of U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc.

Biofrontera AG issued a correction notice regarding its H1 2025 report and a press release dated September 30, 2025. The correction addresses typing errors in the "Outlook and Forecast" sections of both the German and English versions of the report. The corrected EBITDA forecast for 2025 is now EUR 1.5 to 3.5 million, up from the previously stated EUR 0.5 to 1.5 million. Additionally, cash and cash equivalents as of December 31, 2025, are corrected to EUR 1 to 3 million, from EUR 0.5 to 3 million. The updated report is available on the company's website.

Biofrontera AG(B8F.DE)

Pre-announcement of a financial report according to articles 114 - 117 WpHG

Biofrontera reports rise in Q4 revenue, turns profitable

Financial Guidance for FY 2026

PTA-Adhoc: Biofrontera AG: Forecast Increase

PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025